RecruitingMuscular Dystrophy, Facioscapulohumeral
Clenbuterol to Target DUX4 in FSHD
Eligible age
18–75 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
Sponsor: Jeffrey Statland
You may qualify if…
- ✓ Genetically confirmed diagnosis of FSHD type 1 or 2, or have a clinical diagnosis of FSHD type 1 with a first degree relative with confirmed mutation
- ✓ between 18 and 75 years of age
- ✓ with a clinical severity score between 0 and 10
- ✓ Able to walk 30ft without support of another person
- ✓ Showing anti-gravity strength on at least one of the tibialis anterior muscles or having an MRI eligible muscle in the leg for needle biopsy
- ✓ willing and able to provide informed consent
- ✓ agree to follow the contraceptive requirement for duration of the study
You may not qualify if…
- ✕ Pregnant or planning to become pregnant during the conduct of the study
- ✕ have a poorly controlled medical condition
- ✕ Were involved in a study of an experimental agent within 3 months of enrollment
- ✕ Are taking beta-blockers or anabolic agent or potassium wasting diuretics
- ✕ Are taking or are planning to take a GLP-1 Agonist during trial
- ✕ have any condition or contraindication which would interfere with testing or preclude use of beta-agonist
- ✕ Are taking blood thinners or medications which make a needle muscle biopsy contra-indicated
- ✕ Has contraindication to lactose such as galactosmia, lactase deficiency and glucose-galactose malabsorption. For those who are lactose intolerant, the PI will determine acceptability based on tolerance reaction to lactose
Where it's recruiting
Source: ClinicalTrials.gov · NCT06721299 · last updated 2026-02-25